Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Lactose Intolerance

In brief

RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).

Key facts

Study ID
NCT02673749
Run by
Ritter Pharmaceuticals, Inc.
People needed
377
Starts
2016-02-01
Expected to finish
2016-10-01
Last updated by the study team
2018-04-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.